Stevens-Johnson syndrome/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: A safety analysis of clinical trials and FDA pharmacovigilance database-Reference-Cited by-同舟云学术

Stevens-Johnson syndrome/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: A safety analysis of clinical trials and FDA pharmacovigilance database

Published:2021-07 Issue: Volume:37 Page:100951
ISSN:2589-5370
Container-title:EClinicalMedicine
language:en
Short-container-title:EClinicalMedicine

Author:

Zhu Jianhong,Chen Guanghui,He Zhichao,Zheng Yayuan,Gao Siyuan,Li Jianfang,Ling Yin,Yu Xiaoxia,Qiu Kaifeng,Wu Junyan

Publisher

Elsevier BV

Subject

General Medicine

Reference29 articles.

1. Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research;Johnson;Lancet Oncol,2020

2. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis;Xu;BMJ,2018

3. Adverse event profiles of anti-CTLA-4 and Anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS;Ji;Clin Drug Investig,2019

4. Severe adverse cutaneous reactions to drugs;Roujeau;N Engl J Med,1994

5. Cutaneous Immune-Related Adverse Events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management;Muntyanu;J Cutan Med Surg,2020

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor necrosis factor inhibitors enhance corticosteroid therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis linked to immune checkpoint inhibitors: a prospective study;Frontiers in Immunology;2024-08-07

2. Erythema multiforme associated with the immune checkpoint inhibitors: A disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System;Journal of the American Academy of Dermatology;2024-08

3. High risk and low prevalence diseases: Stevens Johnson syndrome and toxic epidermal necrolysis;The American Journal of Emergency Medicine;2024-07

4. Characterizing immune checkpoint inhibitor-related cutaneous adverse reactions: A comprehensive analysis of FDA adverse event reporting system (FAERS) database;Heliyon;2024-07

5. Pulmonary haemorrhage and haemoptysis associated with bevacizumab-related treatment regimens: a retrospective, pharmacovigilance study using the FAERS database;Frontiers in Pharmacology;2024-06-24